Pharmacokinetics, safety and efficacy of a recombinant factor <scp>IX</scp> product, trenonacog alfa in previously treated haemophilia B patients
Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B
Once‐weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9‐GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials
Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial
Guidelines for the management of hemophilia
Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption
Reformulated B<scp>ene</scp>F<scp>ix</scp><sup>®</sup>: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B
Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B
Current management of hemophilia B: recommendations, complications and emerging issues
Emerging drugs for hemophilia B
Barriers to compliance with prophylaxis therapy in haemophilia
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial
Consequences of intra‐articular bleeding in haemophilia: science to clinical practice and beyond
Care models in the management of haemophilia: a systematic review
Adherence to clotting factors among persons with hemophilia A or B
Role of enhanced half‐life factor <scp>VIII</scp> and <scp>IX</scp> in the treatment of haemophilia
Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B
Safe switching from a pdFIX (Immunine<sup>®</sup>) to a <scp>rFIX</scp> (Bax326)
The current status of prophylactic replacement therapy in children and adults with haemophilia
Once‐weekly prophylactic treatment vs. on‐demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B